Tapering Off Antidepressants

Stopped early · Not applicable

Conditions studied: Major Depressive Disorder, Anxiety Disorder, Obsessive Compulsive Disorder, Post-Traumatic Stress Disorder

In brief

The purpose of this study is to compare two ways to stop taking an antidepressant medication and determine whether a faster or slower taper is better tolerated.

Key facts

Study ID

NCT02661828

Run by

Emory University

People needed

2

Starts

2016-01-01

Expected to finish

2017-03-17

Last updated by the study team

2018-09-25

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Currently taking an FDA-approved antidepressant for at least four weeks on the list of approved medications: SSRIs (citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, vilazodone or vortioxetine), SNRIs (desvenlafaxine, duloxetine, levomilnacipran, venlafaxine) and other classes (amitriptyline, bupropion, desipramine, doxepin, mirtazapine, nefazodone, nortriptyline, phenelzine, selegiline, or tranylcypromine). Clomipramine, a tricyclic antidepressant approved for the treatment of OCD, will also be included, but will be classed as an SSRI for this study because inhibition of the serotonin transporter is its primary therapeutic mechanism.
• No longer wish to take the antidepressant medication they are currently prescribed, due to one of the following reasons: 1) ineffective for symptoms; 2) intolerable side effect; 3) improvement of their illness for sufficient duration that it is clinically appropriate to consider tapering the medication.
• Primary psychiatric diagnosis of major depressive disorder, an anxiety disorder, OCD, or PTSD.
• Ability to read and understand English language.

You may not qualify if…

• Has met criteria at any time during their life for a primary psychotic disorder (e.g. schizophrenia), or dementia.
• Meets criteria for DSM-5-defined substance use disorder within three months of the screening visit.
• Currently taking two or more antidepressants.
• Presents with a clinically significant suicide risk, as assessed by a study physician.
• Presence of any unstable or central nervous system-related medical illness that would interfere with cognition or participation.
• Women who are currently pregnant or lactating, or plan to become pregnant during the study.

Where it is running

• Emory University — Atlanta, Georgia, United States
• The Emory Clinic — Atlanta, Georgia, United States
• 12 Executive Park Drive, 3rd floor — Atlanta, Georgia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.